Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death

Abstract Background Sorafenib (Sor) is the only approved multikinase inhibitor indicated for the treatment of HCC. Previous studies have shown that amygdalin (Amy) possesses anticancer activities against several cancer cell lines; we suggested that these compounds might disrupt AMPK/mTOR and BCL-2....

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Tarek El-Sewedy, Afrah Fatthi Salama, Amro E. Mohamed, Nashwa M. Elbaioumy, Ali H. El-Far, Aisha Nawaf Albalawi, Alaa Elmetwalli
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2023-09-01
Ráidu:	BMC Complementary Medicine and Therapies
Fáttát:	HCC AMPK /mTOR Angiogenesis Sorafenib Molecular docking Amygdalin
Liŋkkat:	https://doi.org/10.1186/s12906-023-04142-1
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!